

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-16. (canceled)

17. (currently amended) An isolated protein fraction comprising Factor VIII:C ~~substantially that is~~ free of measurable platelet agglutinating vWF activity as determined by measuring vWF:Risto-CoF activity, where the protein fraction is obtained from a factor VIII/vWF-containing solution by cation exchange chromatography and step-wise elution at a salt concentration of between >200mM and <300mM, wherein the factor VIII/vWF-containing solution is a cryoprecipitate, a supernatant, or an extract of a recombinant cell culture.

18. (withdrawn—currently amended) A preparation comprising ~~factor~~ Factor VIII:C ~~substantially that is~~ free of measurable platelet agglutinating vWF activity, as determined by measuring vWF:Risto-CoF activity, and obtained as set forth in claim 17, wherein said preparation is virus safe and free from infectious material.

19. (withdrawn) A preparation as set forth in claim 18, wherein said preparation is present in storage-stable form.

20. (withdrawn—previously presented) A preparation as set forth in claim 18, wherein said preparation is formulated in buffer as a pharmaceutical preparation.

21. (cancelled)

22. (withdrawn—currently amended) A method of treating patients suffering from at least one of hemophilia A, phenotypic hemophilia and ~~vWF~~ vWD, comprising administering to said patients an effective dose of the ~~factor~~ Factor VIII:C that is substantially

Appl. No. 10/789,562

Amdt. dated June 3, 2009

Reply to Office Action of February 20, 2009

PATENT

free of measurable platelet agglutinating vWF activity, as determined by measuring vWF:Risto-
CoF activity, and obtained as set forth in claim 17.